-
Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions.
AeroVanc™
Savara is currently preparing for its Phase IIa clinical study of AeroVanc's efficacy, to be carried out in 22 cystic fibrosis centers throughout the U.S.
MRSA in CF
MRSA infections have become increasingly common, with a prevalence of almost 30% of the U.S. cystic fibrosis patient population.